Mehmet Sitki Copur, MD, on Inadequacies of the Clinical Trials System Highlighted by COVID-19
The expert oncologist/hematologist spoke with CancerNetwork® about the challenges brought to light by the current pandemic.
The expert oncologist/hematologist spoke with CancerNetwork® about the challenges brought to light by the current pandemic.
Patients who are predisposed to medullary thyroid cancer should be advised against the use of GLP1 agents.
Sacituzumab tirumotecan elicited responses prominently in the second- and third-line and beyond setting and in those with high TROP2 expression.
The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or…
Those aged 18 to 40 years with invasive, HER2-positive breast cancer showed a survival benefit from upfront surgery over neoadjuvant chemotherapy.
TLX101 is currently under assessment as a treatment for glioma in the IPAX-2 and IPAX-Linz studies.
Results from the INSITE trial support the utility of pegulicianine fluorescence-guided surgery during breast cancer surgery.
An increased TIL count in the breast tissue was associated with improved distant recurrence-free survival in patients with triple-negative breast cancer.
The phase 3 TOPAZ-1 trial of durvalumab plus chemotherapy showed a significant benefit vs chemotherapy alone for patients with advanced biliary tract cancer.
A proteogenomic analysis found savolitinib plus osimertinib elicited a response in patients with EGFR-mutated, MET-amplified advanced NSCLC.
Pediatric patients with acute lymphoblastic leukemia/lymphoma were less likely to have severe COVID-19 infection.